Market research
VYNE Vyne Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 2.01
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US92941V2097
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 2.01
About
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VYNE discussion.
5 years, 4 months ago
VYNE Therapeutics Inc is currently in a long term downtrend where the price is trading 50.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.7.
VYNE Therapeutics Inc's total revenue rose by inf% to $4M since the same quarter in the previous year.
Its net income has increased by 68.5% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 54.6% to $-25M since the same quarter in the previous year.
Based on the above factors, VYNE Therapeutics Inc gets an overall score of 3/5.